InvestorWire NewsRoom


InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space
March 15, 2024

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity of chemotherapy, and Sigyn Therapy(TM) to address pathogen-associated conditions that are beyond the reach of drugs. “Though highly valued, [immunotherapeutic antibodies to treat cancer] are limited by poor delivery to cancer cell targets and as a result, most patients do not respond to therapy. Inhibiting the delivery of therapeutic antibodies are circulating decoys that display the binding site target of the antibody and can be highly prevalent in the bloodstream. As a result, a significant portion of an antibody dose can bind to circulating decoys instead of cancer cell targets. ‘Amazingly, with more than 1,000 therapeutic antibodies being evaluated by human studies, there was no strategy to reduce the circulating presence of decoys that block the delivery of these drugs,’” reads a recent article that contains excerpts from Sigyn Therapeutics chairman and CEO James A. Joyce’s letter to shareholders.

“To fill this gap, Sigyn Therapy designed the ImmunePrep platform, whose implementation is based on a reverse decoy mechanism. This mechanism will leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that extract antibody decoys from the bloodstream before the normal delivery of the same therapeutic antibodies.”

To view the full article, visit

About Sigyn Therapeutics Inc.

Sigyn Therapeutics is a development-stage, medical-technology company headquartered in San Diego, California. The company’s therapeutic candidates are designed to overcome clearly defined limitations in healthcare. These include the ImmunePrep(TM) platform, ChemoPrep(TM), ChemoPure(TM) and Sigyn Therapy(TM). ImmunePrep is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for nine of the top 15 best-selling cancer treatment drugs. ChemoPrep is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPure extracts off-target chemotherapy from the bloodstream to reduce patient toxicity. Sigyn Therapy is a novel blood purification technology being advanced to treat pathogen-associated inflammatory disorders. To date, in vitro studies have demonstrated the ability of Sigyn Therapy to reduce the circulating prevalence of 12 different pathogen and inflammatory-disease targets from human blood plasma. Based on these outcomes, candidate treatment indications include community-acquired pneumonia, endotoxemia, drug-resistant viral and bacterial infections, and sepsis, the leading cause of hospital deaths in the United States. First-in-human feasibility studies of Sigyn Therapy plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).